

GIANT CELL TUMOR of BONE

Hsin-Nung Shih M.D. PROFESSOR DIVISION OF JOINT RECONSTRUCTION DEPARTMENT OF ORTHOPEADIC CHANG GUNG MEMORIAL HOSPITAL CHANG GUNG UNIVERSITY,COLLEGE OF MEDICINE TAIWAN

Benign Giant Cell Tumor Of Long Bone History Aspects

1818 Sir Asteley Cooper Benign nature *** 1860 Nelaton** Aggressive ***1865 Virchow Recurrence**, malignant ***1879 Gross** Aneurysmal Benign GCT *1910 Bloodgood *** 1922 Stewart** Osteoclastoma ***1981** Inscrutable high incidence in China *****1985



Giant Cell Tumor of Bone

Benign
Aggressive
Common (18.2% of benign lesion)
F > M
85% > 20 yrs age



Giant Cell Tumor Of Bone Signs and Symptoms

 Aching pain, local swelling, tenderness, limited motion
 Neurologic disturbances
 Not characteristic
 Joint effusion





The Age Different Between ABC And GCT

*78% < 20 yrs age in ABC
*80% > 20 yrs age in GCT
*-- Dahlin 1978



Benign Giant Cell Tumor Of Bone Roentgenographic features

Expanding zone of radiolucency *****Eccentric Metaphysis + Epiphysis No reactive sclerosis No periosteal reaction except pathologic fracture **Cystic** Thin trabeculae







Benign Cell Tumor Of Bone Differential Diagnosis

Aneurysmal bone cyst
Chondroblastoma
Non-ossifying fibroma
Giant cell reparative granuloma
Brown tumor of hyperparathyroidism
Pigmented villonodular synovitis



Trabeculated Lesions In Soap Bubble Tumor

Lesion	Pattern
GCT	Delicate, thin
Chondromyxoid fibroma	Coarse, thick
Non-ossifying fibroma	Loculated
Aneurysmal bone cyst	Delicate, horizontally oriented
Hemangioma	Striated, radiating



Benign Giant Cell Tumor Of Bone Radiographic Differential Diagnosis

	Location	X-ray	Gross
GCT	M+E	Eccentric expanded radiolucency	Freshy soft tissue
NOF	Μ	Eccentric oval defect	
ABC	Μ	Eccentric blow-out, soap bubble	Bloody cavity
Chondroblastoma	E	Radiolucency+spotty opacities	Firm to fleshy tissue
Brown tumor	Any	Absent lamina dura, thin cortex	Fleshy, Cystic

E: Epiphysis M: Metaphysis



Giant Cell Tumor Campanacci's Radiographic Classification





Benign Giant Cell Tumor Radiographic grade Campanacci 1987

- Grade I Well marginated thin rim border cortex intact, slight thin, not deformed
- Grade II Well marginated without rim present thin expanded cortex
- Grade II + fracture
- Grade III Fuzzy borders, rapid ± permeative growth, soft tissue mass



Benign Giant Cell Tumor Of Bone Enneking benign tumor staging system

LatentActiveAggressive

Clinical + X-ray + Bone scan + Angiogram + CT scan + macroscopic + microscopic study

































Benign Gaint Cell Tumor Of Bone Gross pathologic features

Soft, friable, gray to red-brown cystic or necrotic, bloody space yellow foci, lipid-laden histiocytes







Aneurysmal Bone Cyst-like Area In Benign Bone Tumors

Unicameral bone cyst
Giant cell tumor
Chondroblastoma
Chondromyxoid fibroma
Fibrous dysplasia








Benign Gaint Cell Tumor Of Bone Microscopic histologic features

Round to oval mononuclear cells,
Nuclei lack hyperchromatism,
III-defined cytoplasmic zone,
Similar nucli multinucleated giant cell,

Mitotic, all uniform







Benign Gaint Cell Tumor Of Bone Histologic grading

Grade I Stroma inconspicuous Giant cells plentful Grade II Stroma prominent Giant cells decrease Grade III Stroma overtly sarcomatous **Giant cell space A.G.** Huvos 1991





Giant Cell Tumor Pre-op Evaluation

Routine medical evaluation metastatic disease ? Brown tumor ?
Routine roentgenograms
Arteriograms for knee lesions
CT scan in sarcoma or pelvis
Bone scan not particularly



Giant Cell Tumor Treatment Consideration

Anatomic site

- Extent
- * Aggressiveness
- Recurrent lesions
- Recurrent lesions
- Risk of recurrence
- Functional deficit resulting from surgery
- Malignant transformation or metastasis are essentially negligible



Expendable Bones

Fibula, ulna, rib bone of the hand and foot

A. Complete resection B. Curettage and grafting

































Giant Cell Tumor Surgical Alternatives

Curettage v.s. Resection



Giant Cell Tumor Curettage

Offers best functional of restoration
High incidence of local recurrence



Treatment Of Giant Cell Tumor

Curettage
Obtain adequate exposure
Excision of tumor with sharp curette
Use BURR to extend margins





Giant Cell Tumor Curettage Technique

 Avoid contamination soft tissue, donor site
 Consider adjuvant treatment
 Restore integrity of bone bone graft; methylmethacrylate



Treatment of giant cell tumor of long bone.

Shih HN, Chen YJ, Huang TJ, Ho WP, Hsueh S, Hsu RW.

Changgeng Yi Xue Za Zhi. 1996 Mar;19(1):16-23.

From 1981 to 1991, sixty-eight patients with giant cell tumors of their long bones were treated and followed-up at Chang Gung Memorial Hospital. Thirty-three males and thirty-five females between the ages of 14 and 76 (average, 32 years) were followed for an average duration of 3.5 years (range, 2.5 years to 7.3 years). Forty-five primary lesions and 23 cases of recurrent lesions were diagnosed. Seventeen patients were classified as grade II while 51, as grade III. Surgical procedures included intralesional curettage and wide resection. The local recurrent rate following surgery was 13% (9/68). The overall outcome was 85% (58/68) good or excellent results. **Complications included one superficial infection**, 9 local recurrences and 3 fractures of fixation devices. In addition, one patient with a lung metastasis was noted. In the primary lesion group, there were 9 grade II and 10 grade **III lesions treated by curettage and grafting.** Of these 4 grade II and 5 grade III patients had local recurrences. The recurrent rate was 47% (9/19) following intralesional curettage with cancellous bone graft (8/16) or bone cement (1/3). The average period before local

recurrence was 10.4 months. Seven of the 9 recurrent patients received radical resections and allograft reconstruction with good results at short-term followup. The other two patients were lost in follow-up. The cases in the curettage group had shown low recurrent rate (1/10) after 1989 and high recurrent rate (8/9) before 1989 (p < 0.001). The most important factor for local recurrence appeared to be inadequate curettage with similar recurrence rates regardless of the type of bone graft used. A careful approach to the surgical margin including use of a dental burr and local adjuvant treatment with phenol, the rate of local recurrence may be decreased. There were no recurrences in the wide resection group. Although radical resection yield a best chance for cure, the sacrifice of the joint with subsequent arthroplasty resulted a compromise of the joint function.


































Treatment Of Giant Cell Tumor

Adjuvant Method * Chemical cauterization phenol + acid alcohol * Methylmethacrylate * CO2 laser cauterization * Cryotherapy









Bone Cementing

Subchondral bony change
 Comparative analysis of subchondral replacement with PMMA or autogenous bone grafts in dogs
 Frassica FJ, Gorski, Pritchard, Sim and Chao – CORR 293, 1993



In Vivo, Reduction of Subchondral Stiffness

Subchondral stiffness in both gr, 3 wks
12 wks Normal of bone graft 79% of PMMA
No deleterious effect on the articular cartilage (histological and biochemical)
In new bone formation and subchondral porosity in PMMA group
F.J. Frassica – CORR 293, 1993



Giant Cell Tumor Resection

Best chance for cure
 Creates large osseous and soft tissue defect



Giant Cell Tumor Resection

Low incidence of local recurrence Major functional deficit






































































































Giant Cell Tumor Treatment Guidelines

 Less extensive ... curettage and graft
Borderline ... alternative
Very extensive ... resection and reconstruction
















Excision curettage and allografting of giant cell tumor.

Shih HN, Hsu RW, Sim FH.

World J Surg. 1998 May;22(5):432-7.

Between 1987 and 1994 we followed 22 patients with giant cell tumors involving the long bones. Their average age was 31 years (range 17-50 years). Five patients had grade II tumors and the other 17 grade III lesions. The average volume of lesions after curettage was 231 ml (range 56-450 ml). All of the patients underwent a modified excisional curettage, and the cavity was filled with deepfrozen allogenic corticocancellous bone graft with supplementary fixation. Two patients developed postoperative complications including a superficial wound infection in one case and a traumatic tibial plateau fracture in one case. The overall outcome was good or excellent in 91% of the patients (i.e., 20/22 cases). There was no degenerative joint arthritis and, surprisingly, no instance of tumor recurrence. Allograft infection and fracture were not present. An allogeneic cortical strut with cancellous bone graft can be used safely and is effective for grafting cavitary lesions created after complete removal of the tumor.





Treatment Of Giant Cell Tumor Bone Allograft

Advantage
Eliminates need to sacrifice normal structures
Avoids donor site morbidity
Overcome limitation of size, shape and quantity



Excision Curettage and Allografting of Giant Cell Tumor.

World Journal of Surgery 1998













Semistructural Allografting in Bone Defects after Curettage.

Journal of Surgical Oncology 1998



Conclusion

Cortical stent allograft provides increased strength, easy fixation, remodeling of the cystic defect, healing of the fracture and preventing deformity.

Remodeling occurs slowly and may never be complete.















































Treatment of Giant Cell Tumor of the Distal Radius.

Clin Orthop Related Research 2001



Treatment of giant cell tumor of the distal radius.

Cheng CY, Shih HN, Hsu KY, Hsu RW.

Clin Orthop Relat Res. 2001 Feb;(383):221-8.

The results of surgical treatment of giant cell tumors of the distal radius were reviewed in 12 patients between 1982 and 1995. All 12 patients had Grade III lesions. Six of the 12 patients were treated using intralesional curettage with local excision, and the other six patients underwent en bloc resection with total condyle (four of the six by osteoarticular allograft, and the other two by fibular autograft) reconstruction with the aim of preserving the functional joint. There were no early or late complications such as infection, graft fracture, implant failure, or nonunion. No local tumor recurrence was seen in either group during the average followup of 6 years (range, 3-16 years). The best functional result was seen in the patients treated with intralesional curettage. The functional result of the resection group was good, achieving an average of 69% (range, 56%-83%) of their range of motion and 70% (range, 63%-77%) of their grip strength on the contralateral side. Intralesional excision should not be excluded as a possible treatment of Grade III lesions, although en bloc resection was used more commonly for these lesions because of tumor surgery reasons. Grade III lesions were treated with curettage when the tumor did not invade the wrist, destroy more than 50% of the cortex, or break through the cortex with an extraosseous mass in more than one plane. Reconstruction with osteoarticular allograft after en bloc resection is recommended in this nonweightbearing joint when there is contraindication for curettage of the lesion.

Giant-cell tumor of the patella: report of two cases.

Wang IC, Shih HN, Hsueh S, Hsu RW.

Changgeng Yi Xue Za Zhi. 1998 Sep;21(3):338-42.

Two patients with giant-cell tumors of the patella are presented in this report. Both patients were young females who were noted to have had nonspecific anterior knee pain and mild swelling of 1 to 12 months' duration prior to admission to our hospital. Local tenderness over the peripatellar area and slight limitation of full flexion were noted during physical examination. The radiographic presentation of each patella appeared as an expansile and lytic lesion with a thin cortex, without evidence of intra-articular involvement. Chest radiography and routine laboratory examination results were normal. After biopsy, intralesional curettage with phenol cauterization and allograft reconstruction was the preferred treatment in these two patients, with both tumors considered to be stage 2 according to Enneking's staging system. Following surgery, range of motion exercise was started after 6 weeks of immobilization with a long leg splint. Both patients regained full range of motion and were pain free. Radiographically, boneremodeling without evidence of recurrence was noted in both patients 2 years postoperatively.



Recurrence Of Giant Cell Tumor Post-op of bone graft

Roentgenographic features
 Lucency at graft site
 Resorption of bone grafts
 Calcified deposits – soft-tissue recurrences



Benign Giant Cell Tumor Of Bone Recurrence

Campancci Mayo Clinic CGMH
Intralesional 27% 25-30%
Marginal 8% 61%
Wide or Radical 0% 0%
Total 15% 16%



Benign Giant Cell Tumor Of Bone Local Recurrence

Campanacci 1978 2M-9yrs (Ave. 19M) 90% in first 3 yrs
CGMH 1991 10.4M
Recurrence ? Radiography grade
Recurrent cases v.s. primary cases











Giant Cell Tumor

Amputation
 Advanced lesion with massive destruction includes joint
 Multiple recurrences
 Secondary infections



Giant Cell Tumor Sacrum, ilium, spinal column

Difficult diagnosis
Center in the spinal body
Purely lytic lesions





CHANG-GUNG MEMORIAL HOSPITAL LINKOU MEDICAL CENTER TAIWAN



